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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrosing lung disease of unknown cause.
The advent of anti-fibrotic medications known to slow disease progression has revolutionised IPF management in
recent years. However, little is known about the natural history of IPF patients with mild physiological impairment.
We aimed to assess the natural history of these patients using data from the Australian IPF Registry (AIPFR).
Methods: Using our cohort of real-world IPF patients, we compared FVC criteria for mild physiological impairment
(FVC ≥ 80%) against other proposed criteria: DLco ≥ 55%; CPI ≤40 and GAP stage 1 with regards agreement in
classification and relationship with disease outcomes. Within the mild cohort (FVC≥ 80%), we also explored markers
associated with poorer prognosis at 12 months.
Results: Of the 416 AIPFR patients (mean age 70.4 years, 70% male), 216 (52%) were classified as ‘mild’ using FVC≥
80%. There was only modest agreement between FVC and DLco (k = 0.30), with better agreement with GAP (k = 0.50)
and CPI (k = 0.48). Patients who were mild had longer survival, regardless of how mild physiologic impairment was
defined. There was, however, no difference in the annual decline in FVC% predicted between mild and
moderate-severe groups (for all proposed criteria). For patients with mild impairment (n = 216, FVC ≥ 80%),
the strongest predictor of outcomes at 12 months was oxygen desaturation on a 6 min walk test.
Conclusion: IPF patients with mild physiological impairment have better survival than patients with moderate-severe
disease. Their overall rate of disease progression however, is comparable, suggesting that they are simply at different
points in the natural history of IPF disease.
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Background
Idiopathic pulmonary fibrosis (IPF), a progressive fibros-
ing interstitial lung disease (ILD) of unknown cause,
results in respiratory failure and ultimately death.
Historically the median survival is thought to be only
2-5 years [1], and the incidence of IPF appears to be
increasing globally [2]. Recently, two agents – nintedanib
and pirfenidone – have demonstrated efficacy in slowing
the rate of FVC decline as well as impacting on a num-
ber of other important disease outcomes [3–6].
However, each trial focused on cohorts with moderate
physiologic impairment and the ASCEND trial excluded
subjects with a forced vital capacity (FVC) above 90%
predicted [3]. Although post-hoc analyses demonstrate
comparable responses to anti-fibrotic therapy between
participants with preserved lung volumes and those with
more significant impairment, access to anti-fibrotic
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medications has been excluded from patients with lesser
physiological impairment in several drug jurisdictions due
to the limited nature of efficacy data for this cohort [7, 8].
There have been various attempts to define severity of
IPF [9–11]. Physiologic measurements, such as FVC or
diffusion capacity for carbon monoxide (DLco) have
been commonly used [12, 13], as have composite
measures of several physiologic values or demographic
features [14, 15]. The two most commonly used com-
posite scores are the composite physiological index
(CPI) [14] and the GAP (gender, age and physiology)
stage [15]. While both individual physiologic measure-
ments and composite scores predict mortality, the ability
of each to distinguish differences in disease progression
among those with mild disease from those more signifi-
cantly affected remains unknown. Clinically, the FVC
has been used not only as a clinical trial endpoint, but
also by funding authorities worldwide to limit access to
anti-fibrotic medications.
The Australian IPF Registry (AIPFR), launched in
2012, recruits IPF patients from across Australia and a
broad spectrum of impairment exists within its data set.
Using this cohort, we sought to compare the FVC ≥ 80%
with other severity criteria in their ability to distinguish
differences in death and disease progression as measured
by annual FVC decline, between mild and moderate-
severe cohorts. Additionally, we investigated factors
predicting poorer prognosis for patients with mild
physiological impairment, to ascertain whether further
characterisation may help select patients who would
especially merit early drug intervention.
Methods
Participants
The Australian IPF Registry is a multi-centre, prospective,
observational registry of incident and prevalent IPF
patients across Australia. Details regarding the Australian
IPF Registry data collection, structure and operations have
previously been published [16]. The Registry has ethical
approval to operate in all States and Territories and this
analysis has ethical approval from the Sydney Local Health
District ethics committee (protocol No X14–0264). All
participants in the Registry were eligible for inclusion in
this analysis.
Classification of mild disease
Using data from the Registry, patients were categorised
as having mild physiological impairment using four dif-
ferent criteria. The primary analysis focused on FVC ≥
80% predicted (exploratory analysis for FVC ≥ 90%
FVC ≥ 75%, FVC ≥ 70%) [13], as this is the criteria used
clinically to restrict anti-fibrotic therapies in many re-
gions. Secondary analysis included: DLco ≥55% (explora-
tory analysis of DLco ≥50%, DLco ≥40%, DLco ≥30%)
[12]; CPI ≤ 40 (exploratory analysis CPI ≤ 30, CPI ≤ 50)
[14]; GAP stage 1 [15].
Only patients who had all the necessary information
for calculation of all scores were included. The CPI was
calculated using the formula: CPI = 91.0 - (0.65 × %
predicted DLco) - (0.53 × % predicted FVC) + (0.34 × %
predicted FEV1) [14]. The GAP score was calculated
using gender, age and physiology as outlined in Add-
itional file 1: Table S1 [15].
Statistical methods
Data are presented as mean ± standard deviation (SD)
and also range, or n (%), as appropriate. The agreement
between the different criteria used to define mild impair-
ment was assessed using kappa values. Univariable and
multivariable Cox proportional models were performed
to investigate the relationships between baseline vari-
ables, including disease severity classifications, with sur-
vival. All patients who received lung transplantation
were censored at the date of transplant for time to event
analyses. Survival curves were compared using the
Kaplan-Meier method and log rank test.
An unstructured, linear mixed model for changes in
FVC % predicted per year was fitted with random inter-
cepts and slopes to compare the disease trajectory for
patients with mild compared with moderate-severe
physiological impairment, over the entire time of patient
follow up in the Registry. Finally, logistic regression
assessing a composite end-point of death or disease pro-
gression (defined as a relative fall in FVC ≥ 10% and/or
DLco ≥ 15% from baseline) at 12 months was performed
in patients with mild impairment (FVC ≥ 80%) at base-
line, to determine markers associated with poorer short-
term prognosis in this group.
Results
Baseline characteristics
Of the 647 patients in the Australian IPF Registry, there
were 416 patients who had complete data for severity
score measurements at baseline, and so available for in-
clusion in this study. Their baseline characteristics are
displayed in Table 1. Interestingly, though less severe,
patients with mild physiological impairment still had sig-
nificant symptoms as measured by the St George
Respiratory Questionnaire (SGRQ) and University of
California San Diego shortness of breath Questionnaire
(UCSD SOBQ). Comparisons of baseline demographic
parameters of patients excluded from this analysis are
available in Additional file 2: Table S2. Overall, patients
who were excluded were slightly older and had more se-
vere symptoms, similar to patients categorised as severe
impairment using FVC ≤ 80% criteria (Table 1).
There were 114 deaths (27.4%) over a median follow
up period of 2.09 years (IQR 1.56, 2.78 years) providing
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914 patient-years of follow up. 17 (4.1%) patients under-
went lung transplantation during the follow up period.
Agreement of proposed criteria for mild IPF
The FVC ≥ 80% categorised almost equal numbers of pa-
tients as having mild (n = 216, 52%) compared to
moderate-severe impairment (n = 200, 48%), while a
DLco ≥55% classified the least patients as having mild
disease (n = 131, 32%) (Fig. 1). We also undertook
exploratory analysis of other threshold levels and as
expected, the change in threshold values had a
significant impact on the proportion of patients classi-
fied as mild for FVC, DLco and in particular CPI
(Additional file 3: Figure S1).
Mild physiological impairment defined by FVC ≥ 80%
had modest agreement with GAP stage 1 (k = 0.50) and
CPI ≤ 40 (k = 0.48) and only fair agreement with DLco ≥
55% (k = 0.30). CPI ≤ 40 had the best agreement with
other variables including DLco ≥ 55% (k = 0.74) and GAP
Table 1 Baseline characteristics of patients in the Australian IPF Registry




Age, years 416 70.4 (8.6) 71.6 (7.9) 69.0 (9.1) 0.003 31.5 89.9
Male, n (%) 416 290 (69.7%) 125 (57.9%) 165 (82.5%) <0.001
Ever smoker, n (%) 416 308 (74.0%) 160 (74%) 148 (74%) 0.986
BMI, kg/m2 412 28.8 (4.8) 28.9 (5.0) 28.6 (4.6) 0.565 15.8 46.4
FVC, L 416 2.6 (0.8) 2.96 (0.79) 2.30 (0.54) <0.001 0.9 4.8
FVC, % pred 416 81.7 (21.2) 97.3 (16.6) 64.9 (9.8) <0.001 40.9 219.5
FEV1/FVC ratio% 416 82.2 (8.4) 80.1 (8.6) 84.4 (7.5) <0.001 27.0 135.0
DLco, % pred 416 48.5 (16.8) 54.6 (17.4) 41.8 (13.2) <0.001 9.4% 143.7%
CPI 416 45.1 (14.1) 37.5 (13.2) 53.3 (9.7) <0.001 54.2 74.5
GAP stage 416 <0.001
GAP stage 1 192 (46.2%) 152 (70.4%) 40 (20.0%)
GAP stage 2 186 (44.7%) 64 (29.6%) 122 (61.0%)
GAP stage 3 38 (9.1%) 0 (0%) 38 (19.0%)
6MWT distance, m 164 431.0 (119) 433 (115) 430 (122) 0.894 48.0 706.0
Initial SpO2, % 163 95.5 (3.19) 95.8 (3.4) 95.4 (3.1) 0.482 83.0 100.0
End SpO2, % 160 86.2 (7.2) 89.0 (7.0) 84.4 (6.8) <0.001 58.0 99.0
Nadir SpO2, % 153 85.3 (7.1) 87.9 (7.3) 83.6(6.5) <0.001 58.0 99.0
SGRQ 383 43.0 (19.7) 38.7 (19.0) 47.6 (44.8) <0.001 0.0 96.6
UCSD SOBQ 243 40.8 (29.3) 33.7(27.1) 48.6 (29.6) <0.001 0.0 119.0
Cough severity 347 39.5 (23.5) 36.9 (22.9) 42.3(23.9) 0.034 0.0 100.0
Anti-fibrotic therapy 416 102 (24.5%) 52 (24.1%) 50 (25.0%) 0.826
acomparison between mild and severe physiological impairment
Fig. 1 Classification as mild disease using different mild definitions
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stage 1 (k = 0.68). There was good agreement between
GAP stage 1 and DLco ≥ 55% (k = 0.61).
Factors predictive of death
As demonstrated in Table 2, on univariable analysis,
demographic characteristics (age, gender, BMI, smoking
status), physiology, and symptom scores (SGRQ, UCSD
SOBQ), except cough severity (measured at baseline on
a visual analogue scale), all predicted increased mortality
for the entire IPF population.
The presence of mild impairment at baseline (by all
proposed criteria) was also predictive of better survival
than those patients with moderate-severe disease, on
univariable as well as multivariable analysis including
age, gender, BMI and smoking status (Table 3). There
was a wide separation in the Kaplan-Meier curves for
mild versus moderate-severe physiological impairment
(Fig. 2).
Disease progression
The disease progression of patients with mild impair-
ment, measured as change in FVC % predicted per year
compared to those with moderate-severe impairment are
shown in Table 4 and Fig. 3. There was no difference in
the annual rate of FVC% predicted decline between the
mild and moderate-severe cohorts, regardless of the dis-
ease severity classification used, with the predicted
annual fall for the entire cohort calculated at 4.4 units
(of FVC % predicted)/year. In a exploratory analysis, lo-
cally weighted scatterplots of FVC% predicted were con-
structed for patients with mild and moderate-severe
disease and again demonstrated similar disease trajector-
ies in these groups (Additional file 4: Figure S2).
Factors predicting progression or death at 12 month in the
mild disease group
There were 216 patients with FVC ≥ 80% categorised as
having mild impairment. Overall, these patients had
preserved lung volume with a mean FVC of 97.3%
predicted, DLco of 54.6% predicted and were mostly
categorised as GAP stage 1 (70.4%) with the remainder
as GAP stage 2 (29.6%). Unsurprisingly, they were less
symptomatic than those with more severe disease,
though they still had significant symptoms. Interestingly,
patients with mild impairment were slightly older and
more likely to be female (Table 1).
Within the cohort of patients with mild impairment,
the prognostic markers which predicted death or pro-
gression at 12 months were evaluated using univariable
logistic regression. There were 22 patients (10.2%) who
died or progressed within 12 months. The only factor
that predicted death or progression at 12 months was
oxygen desaturation during 6 min walk testing at base-
line (OR 0.89, 95% CI 0.81, 0.98; p = 0.024 for every 1%
change in nadir SpO2) (Table 5).
Unsurprisingly, within this cohort with mild impair-
ment, other lung function parameters and composite
scores were not predictive of death or progression. On a
multivariable logistic regression model including age,
gender, BMI and smoking status, nadir oxygen satur-
ation during 6MWT remained a significant predictor of
poorer outcome (OR 0.89, 95%CI 0.80, 0.98; p = 0.024).
Discussion
In our cohort of IPF patients from the Australian IPF
Registry, we demonstrate that a significant proportion of
Table 2 Univariable Cox analysis
n HR 95% CI p
Age 416 1.03 1.01 1.05 0.013
male 416 1.96 1.25 3.08 0.003
BMI 412 0.94 0.89 0.98 0.003
Smoking 416 1.93 1.20 3.11 0.007
Physiology
FVC (L) 416 0.56 0.43 0.74 <0.001
FVC (%pred)a 416 0.71 0.64 0.79 <0.001
DLco (%pred)a 416 0.56 0.49 0.64 <0.001
6MWDb 164 0.82 0.73 0.92 0.001
SpO2 at rest 163 0.88 0.82 0.95 0.001
SpO2 at end 160 0.92 0.88 0.95 <0.001
SpO2 nadir 153 0.92 0.89 0.96 <0.001
CPI 416 1.09 1.07 1.11 <0.001
GAP stage 416 4.48 3.37 5.95 <0.001
Patient reported outcomes
SGRQ totalc 383 1.11 1.06 1.15 <0.001
UCSD SOBQa 243 1.23 1.13 1.33 <0.001
Cough severitya 347 1.08 0.99 1.17 0.069
BMI body mass index, FVC forced vital capacity, DLco diffusion capacity for carbon
monoxide, CPI composite physiological index, GAP gender age physiology, 6MWD
6 min walk distance, SpO2 peripheral blood oxygen saturation, SGRQ St George’s
Respiratory Questionniare, UCSD- SOBQ University of California San Diego
shortness of breath questionnaire. aFor every 10 unit change; b for every 50 m
change; cfor every 4 point change
Table 3 Univariable and multivariable Cox analysis for disease
severity
HR 95% CI p HR 95% CI p
Univariable analysis Multivariable analysisa
FVC < 80% 3.21 2.17–4.75 <0.001 3.15 2.11–4.71 <0.001
DLco < 55% 6.28 3.28–12.03 <0.001 5.55 2.88–10.70 <0.001
CPI > 40 7.28 3.90–13.57 <0.001 6.60 3.52–12.39 <0.001
GAP stage 1 7.09 4.27–11.76 <0.001 7.44 4.18–13.25 <0.001
aMultivariable model includes age, gender, BMI and smoking status and
includes 412 of 416 available for univariable model
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IPF patients have mild physiological impairment; though
this proportion varied depending on the criteria and
threshold used to define mild impairment. We demon-
strate that the agreement for mild impairment using
FVC ≥ 80% was modest to fair with other proposed cri-
teria. We also show that patients who are mild have bet-
ter survival than patients those with moderate-severe
physiological impairment. Importantly, we show that pa-
tients with mild impairment, regardless of the criteria
for categorisation used, have a similar annual rate of
Fig. 2 Kaplan Meier analysis for time to death by disease category. a. Kaplan Meier analysis according to FVC 80%. Log rank test p < 0.001. b. Kaplan
Meier analysis according to DLco 55%. Log rank test p < 0.001. c. Kaplan Meier analysis according to CPI 40. CPI (composite physiological index). Log
rank test p < 0.001. d. Kaplan Meier analysis according to GAP stage. GAP (Gender, Age, Physiology). Log rank test p < 0.001
Table 4 Annual FVC % predicted decline by disease category
and severity
mild 95% CI more severe 95% CI Pa
FVC −4.6% −5.8;-3.4% −4.9% −6.3; −3.5% 0.779
DLco −4.9% −6.0;-3.8% −4.7% −5.7; −3.7% 0.702
CPI −5.0% −6.3; −3.6% −4.5% −5.7; −3.3% 0.600
GAP −5.0% −6.3; −3.8% −4.4% −5.8; −3.0% 0.517
acomparison of mild to moderate-severe group
Fig. 3 Decline in FVC % predicted in mild (FVC≥ 80%) compared with
moderate-severe (FVC < 80%) physiological impairment. Graphical
representation of annual FVC% decline as calculated by unstructured
linear mixed model with random intercept and slopes for mild and
moderate-severe disease
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decline in FVC % predicted compared to those with
more severe impairment. Finally, we show that in pa-
tients with mild impairment, the prognostic marker
most predictive of death or progression at 12 months
was oxygen desaturation on the 6 min walk test
(6MWT).
One important finding of this study was that IPF pa-
tients with mild physiological impairment had the same
disease trajectory, with comparable annual decline in
FVC to those with moderate-severe disease. This mirrors
the results found in the post-hoc analysis of pirfenidone
[8] and nintedanib trial cohorts [7] whereby patients
with mild physiological impairment were shown to have
comparable disease progression at 12 months to their
more severe counterparts. Unlike the clinical trial
cohorts however, Registry patients are real-world,
unselected IPF patients with frequent significant co-
morbidities. Registry patients also have a wide spectrum
of IPF disease severity with 68 patients below the thresh-
old for inclusion in clinical trials (FVC < 50%, n = 9;
DLco <30% n = 47, and n = 6 for both), and are managed
by respiratory physicians throughout Australia, not lim-
ited to tertiary referral centres. The reproducibility of
this finding in this heterogeneous cohort strengthens the
generalisability of the post-hoc analysis from the large
therapeutic clinical trials [7, 8]. It is also important to
note that even patients with mild physiological impair-
ment had significant symptoms. Ultimately, these results
suggest that patients with preserved physiology are likely
to represent an earlier stage of the natural history of IPF,
rather than a separate and milder cohort of IPF patients
with a specific natural history.
Another important finding of our study was that
within the cohort of patients with mild impairment, the
degree of oxygen desaturation on the 6MWT was the
only significant short-term prognostic marker. Whilst
previous studies have demonstrated that the 6MWT
distance [17–19] and oxygen desaturation [20, 21] on
6MWT can predict mortality in IPF, this test is often not
performed on a regular basis (as demonstrated in this
study by the smaller number of patients who have had
this test). The desaturation on the 6MWT is likely to
represent a complex interplay between, and cumulative
impact of, the physiological changes that occur in IPF
including pulmonary hypertension, ventilation/perfusion
mismatch and diffusion limitation. Our data suggests
that in a cohort with relatively preserved lung function,
where individual pulmonary function variables provide
no additional prognostic value, the performance of the
6MWT is prognostically important.
We also highlight the differences between various
proposed criteria for IPF severity, reflecting the need for
a standardised approach to disease severity stratification.
While we found in our cohort a significant overlap using
these various definitions for mild physiological impair-
ment, there were also significant discrepancies. Further-
more, there was only fair concordance between FVC and
DLco, with the FVC ≥80% classifying more patients as
mild than DLco ≥55%. This likely reflects the effects of
the pulmonary function thresholds chosen, and was
highlighted by the considerable variability in classifica-
tion with different thresholds used in the exploratory
analysis (see Additional file 3). The better concordance
with composite values, as opposed to between single
measures such as FVC and DLco, arises from the fact
that both these single measures contribute to the calcu-
lation of the composite scores. It is interesting to note
that the DLco and the composite scores were better at
predicting survival suggesting that, while it is commonly
used, the FVC threshold may not be the most clinically
useful criteria.
Our study has several limitations. Firstly, this was a
retrospective analysis of a prospective observational
study and all investigations were performed as part of
the patients’ routine clinical care, resulting in some vari-
ability in the investigations performed. In particular, in
clinical practice in Australia, there is variability between
centres in routinely undertaking a 6MWT, for which we
had baseline data for 164 individuals overall, and 63 pa-
tients in the groups with FVC ≥ 80%. Despite the limited
numbers, we were able to show a significant difference
in outcomes, highlighting the strength of this
Table 5 Logistic regression for death or disease progression at
12 months in patients with FVC ≥ 80%
n OR 95% CI p
Age 216 0.99 0.94 1.05 0.847
male 216 0.86 0.35 2.09 0.739
BMI 212 1.00 0.92 1.10 0.954
Ever smoker 216 0.93 0.34 2.50 0.879
FVC % preda 216 0.81 0.56 1.16 0.241
DLco %preda 216 0.87 0.67 1.14 0.312
CPIa 216 1.26 0.86 1.86 0.234
GAP stage 216 1.12 0.43 2.90 0.813
6 MWDb 63 0.75 0.54 1.04 0.083
SpO2 at start 63 0.86 0.71 1.03 0.108
SpO2 at end 63 0.89 0.81 0.98 0.021
SpO2 nadir 59 0.89 0.81 0.98 0.024
SGRQc 199 1.02 0.93 1.12 0.688
UCSD SOBQa 126 1.00 0.77 1.28 0.970
Cough severitya 177 1.16 0.95 1.41 0.136
BMI body mass index, FVC forced vital capacity, DLco diffusion capacity for carbon
monoxide, CPI composite physiological index, GAP gender age physiology, 6MWD
6 min walk distance, SpO2 peripheral blood oxygen saturation, SGRQ St George’s
Respiratory Questionniare, UCSD- SOBQ University of California San Diego
shortness of breath questionnaire. aFor every 10 unit change; b for every 50 m
change; c for every 4 point change
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association, a finding that we hope will now affect na-
tional clinical practice. Also, while there is a standar-
dised guide for the 6MWT, there is likely to be variation
between centres. The potential importance of this asso-
ciation between desaturation on 6MWT and prognosis
also highlights the importance of confirming these find-
ings in a larger, prospective cohort with standardised
testing.
Conclusion
In summary, accurate clinical staging has important im-
plications in IPF as it can inform initial patient manage-
ment, prognostication and standardisation of clinical
trials and their outcomes. Patients with mild physio-
logical impairment have better overall survival, although
their rate of disease progression appears the same as
seen in those with moderate-severe impairment, with
differences in outcome being attributable to where the
patient sits in the natural history of their disease. Given
their apparent identical disease trajectory and significant
symptoms, this study adds impetus to the view that
patients with mild impairment be offered anti-fibrotic
therapy early in their disease course. This is particularly
so for those with significant desaturation on the 6MWT,
as they appear to have the poorest outcomes.
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